Is AbbVie a biomedical company?

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection.

What makes AbbVie unique?

Our combination of focused innovation and commercial scale brings differentiated products to market that benefit patients, customers and health care providers. AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

When did AbbVie become a spin-off company?

This spin-off company, named AbbVie, was formed on April 10, 2012. The separation was fully effective January 1, 2013, and AbbVie was officially listed on the New York Stock Exchange (ABBV) on January 2, 2013.

Will AbbVie buy cerevel Therapeutics?

In December 2023, AbbVie announced that it will acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion, in an attempt to expand its drug pipeline. the company expects to complete the acquisition in the middle of 2024.